Piramal Pharma gets US FDA EIR for Digwal in 2026

What the company disclosed to exchanges

Piramal Pharma Ltd informed stock exchanges that the United States Food and Drug Administration (US FDA) has issued an Establishment Inspection Report (EIR) for its manufacturing facility at Digwal, Telangana. The issuance of the EIR indicates the inspection has been successfully closed by the regulator. The company described Digwal as its flagship plant in the filing updates referenced in market reports.

For investors, the EIR matters because it signals that the FDA has formally concluded its review of the site. In US regulatory parlance, an EIR generally means the inspection is closed and the facility’s operations were found compliant with current Good Manufacturing Practices (cGMP), as stated in the provided context.

Digwal inspection context: dates and observations

The US FDA conducted a general GMP inspection of Piramal Pharma’s Digwal facility from 9 February 2026 to 13 February 2026. At the conclusion of that inspection, the US FDA issued a Form 483 with four observations.

The company has said the observations were related to enhancement in procedures and were not related to data integrity. It also indicated that the observations were expected to be classified as VAI (Voluntary Action Indicated), and that a detailed response would be submitted within stipulated timelines.

What an EIR signals in US FDA inspections

An Establishment Inspection Report (EIR) is the FDA’s written record that closes out an inspection. The context provided states that an EIR signifies the US FDA has formally closed an inspection and found the facility’s operations compliant with cGMP.

While companies can still have follow-up actions based on inspectional findings, market participants typically treat EIR issuance as a reduction in uncertainty around a site’s regulatory status. The update on Digwal therefore addresses a key operational concern for the plant.

Regulatory status moves to “Successfully Closed”

Market commentary included in the provided material noted that Digwal’s status has moved from “Under Inspection” to “Successfully Closed”. This shift is often viewed as meaningful because it removes what traders commonly describe as a regulatory overhang.

The same commentary also linked the milestone to Piramal Pharma’s manufacturing base that supports global Active Pharmaceutical Ingredient (API) exports. The focus on API exports is important because US compliance is a prerequisite for many supply relationships.

Facility capacity and export visibility

The supplied market snapshot stated that export visibility for the US market is now secured for the 750 kL capacity Digwal facility. No additional capacity or utilisation details were provided, so the update is limited to the capacity figure and the stated improvement in export visibility.

In practical terms, an inspection closure can support smoother customer engagement and planning, especially when clients require evidence that regulatory inspections are completed and documentation is in place.

Stock and trading cues highlighted by the market

The provided text noted that the stock saw a 14.03% volume-backed surge on May 7, which was described as reflecting heightened institutional interest. Separately, one market report cited that Piramal Pharma shares ended 1.69% higher at Rs 165.90 on BSE in the previous session, with a market capitalisation of Rs 22,052 crore.

Two separate price snapshots were also included in the material, alongside 5-day and year-to-date style changes, and analyst target information.

Key facts table

Price and target references cited in reports

The dataset included references to “Last Close Price” and average target prices from market sources. One snapshot showed a last close of Rs 172.79 with an average target price of Rs 203.00, and a spread to average target of +17.48%. Another snapshot listed an average target price of Rs 200.10 alongside a last close reference of Rs 148.79.

Financial backdrop mentioned in the same material

Alongside the regulatory update, the compiled text referenced recent financial performance pressures. It stated Piramal Pharma slipped into the red in the September quarter, reporting a consolidated net loss of Rs 99 crore, compared with a profit of Rs 23 crore in the same period last year.

It also said revenue from operations fell 9% year-on-year to Rs 2,044 crore in Q2FY26. In another reference to segment performance, the material stated that the CDMO business constitutes roughly 59% of revenues and saw 11% YoY growth to Rs 1,021 crore in the cited period.

Other US FDA inspection references in the background

The material also contained references to other Piramal Pharma facilities that have been inspected in recent years. For the Lexington facility in Kentucky, it stated the US FDA conducted a general GMP inspection from December 3 to December 10, 2025, following which a Form 483 with four observations was issued and the company expected a VAI classification.

It further referenced a Turbhe facility inspection from February 11 to February 17, 2025, which resulted in a Form 483 with six observations. Another historical reference said the US FDA concluded an inspection at the Sellersville manufacturing facility conducted between December 19, 2022 and January 13, 2023, after which an EIR was issued.

Market impact and why this update matters

Regulatory approvals and closures are generally viewed as positive fundamental triggers, as noted in the supplied text. In Digwal’s case, the EIR issuance directly addresses compliance uncertainty around a key manufacturing facility linked to API exports.

The provided market bias commentary described the setup as bullish, arguing that EIR receipt for a high-capacity facility removes regulatory risk and could help recent operating momentum translate better into earnings. That commentary also referenced 28.16% QoQ topline growth and a $10 million global expansion, and pointed to expectations of early-to-mid teens revenue growth in the coming fiscal year, as stated.

Conclusion

Piramal Pharma’s update that the US FDA has issued an EIR for its Digwal, Telangana facility confirms that the regulator has successfully closed the inspection conducted in February 2026. The closure follows a Form 483 with four observations that the company said related to procedural enhancements and not data integrity.

With Digwal’s status described as “Successfully Closed” in market commentary, attention now shifts to how the company executes its planned responses and timelines across facilities while navigating the operational backdrop highlighted in its recent financial performance disclosures.